贵州益佰制药股份有限公司关于收到贵州省药品监督管理局《暂停生产、销售通知书》的公告

Group 1 - The company received a suspension notice from the Guizhou Provincial Drug Administration, requiring an immediate halt to the production and sale of its children's cough syrup due to regulatory non-compliance [1][2] - The suspension was based on findings from an inspection by the National Medical Products Administration, which identified deficiencies in record-keeping and data reliability [1][2] - The children's cough syrup generated revenues of 3.42 million, 4.32 million, 8.38 million, and 1.51 million yuan in 2021, 2022, 2023, and 2024 respectively, accounting for 0.10%, 0.16%, 0.30%, and 0.07% of the company's total revenue, indicating a relatively small impact on overall performance [2] Group 2 - The controlling shareholder, Dou Qiling, holds 185,457,636 shares, representing 23.42% of the total share capital, and has released part of the pledged shares [5][6] - After the release of the pledge, Dou Qiling has a total of 64,560,000 shares pledged, which is 34.81% of her holdings and 8.15% of the company's total shares [6] - The company will fulfill its disclosure obligations if the released shares are used for other pledge activities in the future [6]